Full Text View
Tabular View
Study Results
Related Studies
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
This study has been terminated.
( Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury. )
Study NCT01244620   Information provided by Pfizer

First Received on November 15, 2010.   Last Updated on January 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Arterial Hypertension
Additional conditions recognized in this trial
Hypertension
Hypertension, Pulmonary
More general conditions related to this trial
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Interventions listed in this trial
sitaxentan
tadalafil
sitaxsentan
sildenafil
More general drug interventions related to this trial
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services